Abstract

Core B, Pathology, will provide histologic, immunohistochemical, immunofluorescence, and ultrastructural analyses of animal and human specimens for each project. 1. Morphologic analyses on interaction of neuroblastoma cells and stroma cells in tumor progression, invasion, metastasis, and bone destruction using animal models and human samples (Project 1). 2. Histologic and immunohistochemical analyses of immune-mediated """"""""tumor cell killing"""""""" in neuroblastomas by using animal models and human tissues (Project 2). 3. Histologic and immunohistochemical analyses of tumors and normal organs of mice treated with retinoids and modifiers (Project 3). 4. Histologic analyses of neuroblastomas to confirm diagnosis and risk classification, as required by clinical study (Project 4).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081403-08
Application #
7719712
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
8
Fiscal Year
2007
Total Cost
$51,852
Indirect Cost

  Institution

Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027

  Publications

Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi et al. (2018) Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer 65:e26940
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Webb, Matthew W; Sun, Jianping; Sheard, Michael A et al. (2018) Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143:1483-1493
Marachelian, Araz; Villablanca, Judith G; Liu, Cathy W et al. (2017) Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 23:5374-5383
Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157
Tran, Hung C; Wan, Zesheng; Sheard, Michael A et al. (2017) TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res 23:804-813
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Zheng, Tina; Ménard, Marie; Weiss, William A (2017) Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell 32:395-397

Showing the most recent 10 out of 150 publications